Plavix® Drug Studies
In March 2010, the FDA issued a black box warning change to Plavix® indicating that the drug is markedly less effective to patients who cannot metabolize the inactive drug form into the active drug form. See FDA Medwatch
Two independent studies, published in the New England Journal of Medicine and the Archives of Internal Medicine, both clearly indicate a substantial increased bleeding risk for patients taking Plavix® both with and independent of an aspirin regimen. The NEJM study notes that while the pharmacological risks are higher in patients treated with clopidogrel, the bigger danger to patients is the lack of monitoring patients on Plavix® receive since the drug was touted as a drug that reduced the need for intense monitoring.